| Ytd | 68.50% | |
| 1y | 70.57% |
| Open | 36.19 | Prev Close | 36.55 | Low | 35.02 | High | 36.19 | Mkt Cap | 558.53M |
| Vol | 9.96K | Avg Vol | 207.96K | EPS | -4.55 | P/E | -7.77 | Forward P/E | -4.85 |
| Beta | 1.70 | Short Ratio | 7.15 | Inst. Own | 110.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 33.13 | 200-d Avg | 25.35 | 1yr Est | 52.80 |
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring
U.S. stock futures lower, Dow futures down 1%. Yatsen Holding shares fall 10.1%, while other stocks
U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares
Autodesk Inc (ADSK) rose sharply after beating Q4 earnings & issuing strong guidance. Other gain
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty i
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease